Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | TYR | P14679 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22290905 | 0.82 | TSHR (0.40) | TSHRTP53NAPRTDAOSRD5A2 | |
| SCHEMBL3543689 | 0.82 | TSHR (0.40) | TSHRTP53NAPRTDAOSRD5A2 | |
| SCHEMBL31427488 | 0.79 | PKM (0.34) | CES2CES1AKR1B1 | |
| SCHEMBL21408507 | 0.77 | MAOA (0.38) | TSHRTP53NAPRTDAOSRD5A2 | |
| SCHEMBL4900653 | 0.77 | BCHE (0.36) | TSHRTP53NAPRTDAOSRD5A2 | |
| SCHEMBL22639055 | 0.73 | — | — | |
| SCHEMBL23421081 | 0.71 | — | — | |
| SCHEMBL1866981 | 0.71 | — | — | |
| SCHEMBL600724 | 0.71 | — | — | |
| SCHEMBL369526 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008780-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2026-01-08 | — | — | US | disclosed |
| US-12215116-B2 | Arginase inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-02-04 | — | — | US | disclosed |
| CN-114173787-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 杨森科学爱尔兰无限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021256861-A1 | NOVEL ACID SECRETION INHIBITOR AND USE THEREOF | 일동제약(주) | 2021-12-23 | — | — | WO | disclosed |
| WO-2020214921-A1 | SOLID FORMS OF MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-22 | — | — | WO | disclosed |
| EP-3697774-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | Vertex Pharmaceuticals Incorporated (US) | 2020-08-26 | — | — | EP | disclosed |
| WO-2019079760-A1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-04-25 | — | — | WO | disclosed |
| EP-2857403-B1 | PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2018-10-10 | — | — | EP | disclosed |
| US-9724352-B2 | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-08-08 | — | — | US | disclosed |
| US-20170000800-A1 | PYRROLO[2,1-F[1,2,4]TRIAZINE COMPOUNDS, PREPARATION METHODS AND APPLICATIONS THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-01-05 | — | — | US | disclosed |
| US-9447101-B2 | Pyrrolo[2,1-f][1,2,4]triazine compound, and preparation method and application thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2016-09-20 | — | — | US | disclosed |
| US-20150141644-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-05-21 | — | — | US | disclosed |
| EP-2857403-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2015-04-08 | — | — | EP | disclosed |
| US-5284681-A | Bringing into contact with water, drying in air | SUMITOMO CHEMICAL CO., LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| US-4451658-A | DECARBOXYLATION WITH MINERAL ACID, ALKANOL, AND WATER | ETHYL CORPORATION (US) | 1984-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000800-A1 | PYRROLO[2,1-F[1,2,4]TRIAZINE COMPOUNDS, PREPARATION METHODS AND APPLICATIONS THEREOF | PIK3CA, PIP4K2B, PIK3R5 | TSHR 1286/4885TP53 127/4885NAPRT 3860/4885 |
| US-20150141644-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF | PIK3CA, PIK3R5, PIP4K2B | TSHR 1229/4885TP53 146/4885NAPRT 3627/4885 |
| US-20260008780-A1 | SUBSTITUTED 3,4-DIHYDROISOQUINOLIN-1(2H)-ONE DERIVATIVES AND RELATED USES | NOD1, NLRP3, CASP1 | TSHR 3816/4885TP53 456/4885NAPRT 1027/4885 |
| US-12215116-B2 | Arginase inhibitors and methods of use | ARG1, ARG2, PRMT1 | TSHR 2028/4885TP53 4159/4885NAPRT 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.